BBP-671 ( DrugBank: - )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
245プロピオン酸血症1
246メチルマロン酸血症1

245. プロピオン酸血症


臨床試験数 : 13 薬物数 : 17 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 6
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04836494
(ClinicalTrials.gov)
March 25, 202129/3/2021A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic AcidemiaA First-in-human, Randomized, Placebo-controlled, Single and Multiple Ascending Dose Escalation to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBP-671 in Healthy Subjects and In Patients With Propionic Acidemia or Methylmalonic AcidemiaHealthy Volunteers;Propionic Acidemia;Methylmalonic Acidemia;Organic AcidemiaDrug: BBP-671;Drug: PlaceboCoA Therapeutics, Inc., a BridgeBio companyNULLRecruiting18 Years55 YearsAll128Phase 1United States

246. メチルマロン酸血症


臨床試験数 : 19 薬物数 : 26 - (DrugBank : 3) / 標的遺伝子数 : 17 - 標的パスウェイ数 : 23
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04836494
(ClinicalTrials.gov)
March 25, 202129/3/2021A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic AcidemiaA First-in-human, Randomized, Placebo-controlled, Single and Multiple Ascending Dose Escalation to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBP-671 in Healthy Subjects and In Patients With Propionic Acidemia or Methylmalonic AcidemiaHealthy Volunteers;Propionic Acidemia;Methylmalonic Acidemia;Organic AcidemiaDrug: BBP-671;Drug: PlaceboCoA Therapeutics, Inc., a BridgeBio companyNULLRecruiting18 Years55 YearsAll128Phase 1United States